Venus Remedies share news and announcements
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,404.30down ₹37.20 (2.58%)BSE ₹1,396.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,441.50.
52-week range of traded prices to 23 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,877 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 Jul 2026
- 16.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 2.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 Jul 2026
- 19.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 Jul 2026
- 21.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day.
- 52,800
Venus Remedies routine notices
118 filed, newest first. Page 3 of 3.
Jan 2021
27 Jan · Routine
20 Jan · Routine
18 Jan · Routine
Nov 2020
11 Nov · Routine
7 Nov · Routine
Oct 2020
Jul 2020
Mar 2020
Jan 2020
Sep 2019
Jun 2019
Apr 2019
Jun 2016
May 2016
Feb 2016
2 Feb · Routine
In terms of SEBI (Prohibition of Insider Trading) Regulations, the Trading Window, for dealing in securities of the Company shall be closed from February 02, 2016 to February 12, 2016 (Both days inclusive) for all the designated employees.